Evidence map›Paper›PMID 39759879›Full record

ArticleMolecular therapy. Nucleic acids2025

Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer.

Vladimira Zlinska, Zuzana Feketova, Aleksandra Czyrek, Julia Chudzian, Martina Lenarcic Zivkovic, Vlad-Constantin Ursachi, Pooja Dudeja, Bohumil Fafilek, Jan Rynes, Gustavo Rico-Llanos and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Lockpicking FGFR1 with aptamer-based technology.Molecular therapy. Nucleic acids · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Vladimira ZlinskaCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czechia.
Zuzana FeketovaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Aleksandra CzyrekDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Julia ChudzianDepartment of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland.
Martina Lenarcic ZivkovicSlovenian NMR Centre, National Institute of Chemistry, 1000 Ljubljana, Slovenia.
Vlad-Constantin UrsachiDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Pooja DudejaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Bohumil FafilekDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Jan RynesCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czechia.
Gustavo Rico-LlanosDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Adolf KoudelkaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Tanaya RoyDepartment of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA.
Martyna BiadunDepartment of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland.
Vendula RaskovaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Katerina SvozilovaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Michaela StroblovaDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.
Mateusz KrzyscikDepartment of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA.
Kalina HristovaDepartment of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA.
Daniel KrowarschDepartment of Protein Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland.
Silvie Foldynova-TrantirkovaCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czechia.
Malgorzata ZakrzewskaDepartment of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland.
Lukas TrantirekCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czechia.
Pavel KrejciDepartment of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impaired fibroblast growth factor receptor (FGFR) signaling is associated with many human conditions, including growth disorders, degenerative diseases, and cancer. Current FGFR therapeutics are based on chemical inhibitors of FGFR tyrosine kinase activity (TKIs). However, FGFR TKIs are limited in their target specificity as they generally inhibit all FGFRs and other receptor tyrosine kinases. In the search for specific inhibitors of human FGFR1, we identified VZ23, a DNA aptamer that binds to FGFR1b and FGFR1c with a K

Indexed as

craniosynostosisDNA aptamerextracellular domainFGFR1FGFR signalinginhibitorMT: Oligonucleotides: Therapies and Applicationsskeletal dysplasia

Identifiers

PMID39759879
PMCPMC11700292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.